Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
Abstract
Broadly protective vaccines against known and pre-emergent coronaviruses are urgently needed. Critical to their development is a deeper understanding of cross-neutralizing antibody responses induced by natural human coronavirus (HCoV) infections. Here, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of pre-existing memory B cells (MBCs) elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a new target for the rational design of pan-sarbecovirus vaccines.
Competing Interest Statement
AZW, DPM, MS, AL, JHN, EC, IB, MB, SL, MS, CJ, SP, LMW Are employees and equity holders in Adimab LLC
Subject Area
- Biochemistry (11715)
- Bioengineering (8723)
- Bioinformatics (29128)
- Biophysics (14935)
- Cancer Biology (12049)
- Cell Biology (17359)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14144)
- Epidemiology (2067)
- Evolutionary Biology (18268)
- Genetics (12221)
- Genomics (16767)
- Immunology (11843)
- Microbiology (28014)
- Molecular Biology (11560)
- Neuroscience (60810)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10384)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)